Stroke in the Covid-19 era
- 01:11
Statistics on the incidence of stroke
- 02:00
The effect of Covid infection on the mortality from stroke
- 03:07
Stroke pathogenesis in patients with COVID-19
- 04:35
Stroke help structure with a stroke
- 06:00
Diagnostic minimum and hospitalization
- 07:15
Differential diagnosis and enhanced attention to diagnosis
- 09:28
Differences in clinical recommendations
- 10:13
Primary and secondary neurocytoprotext and criteria for the choice of drugs
- 14:01
Evidence base of neurocytoprotective therapy
- 16:00
The effectiveness of the drug Mexidol® based on the results of an epic study
Evgeniya Viktorovna Yekusheva – Doctor of Medical Sciences, Professor, Head of the Department of Nervous System Diseases and Neurorehabilitation of the Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia
Ivan Aleksandrovich Shchukin – PhD, Associate Professor of the Department of Neurology, Neurosurgery and Medical Genetics of the Leningrad Branch of the N.I. Pirogov Russian National Research Medical University
Announcement:
During the COVID-19 pandemic, stroke mortality has increased. Stroke development in COVID-19 patients may be associated with various risk factors, such as hypertension and atherosclerosis. The virus can also trigger a cytokine storm and a systemic inflammatory response, which contribute to the development of ischemic stroke. Hemorrhagic stroke is more often associated with COVID-19-associated coagulopathy and red blood cell hemolysis. Stroke patients who have recovered from COVID-19 often require constant assistance with daily living. The structure of care for these patients has not changed, but new clinical methods for managing them have been developed. Taking Mexidol® after COVID-19 has the following effects: membrane protection, antihypoxic action, antioxidant action, and more. Learn more about the effects, as well as taking Mexidol® after stroke and treatment after COVID-19, in our video.
- 01:11
Statistics on the incidence of stroke
- 02:00
The effect of Covid infection on the mortality from stroke
- 03:07
Stroke pathogenesis in patients with COVID-19
- 04:35
Stroke help structure with a stroke
- 06:00
Diagnostic minimum and hospitalization
- 07:15
Differential diagnosis and enhanced attention to diagnosis
- 09:28
Differences in clinical recommendations
- 10:13
Primary and secondary neurocytoprotext and criteria for the choice of drugs
- 14:01
Evidence base of neurocytoprotective therapy
- 16:00
The effectiveness of the drug Mexidol® based on the results of an epic study
Block of articles on this topic
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com